8-WEEK RAPID RESPONSE:
Clinical response† was achieved as early as Week 8 in UC (secondary endpoint) clinical trials1
Clinical remission‡§ was achieved at 1 year in a UC clinical trial1
STELARA® has a proven safety profile through 1 year. Plus safety data through 4 years (from Phase 3 studies and open-label LTE)1,2
For patients with commercial or private insurance
STELARA withMe Savings Program
Eligible patients pay $5 per dose.
Maximum program benefit per calendar year shall apply.
STELARA withMe Savings Program: Eligible patients using commercial insurance to pay for their medication can save on their out-of-pocket medication costs for STELARA®. Eligible patients pay $5 per dose. Maximum program benefit per calendar year shall apply. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their treatment. See full eligibility requirements
CD=Crohn’s disease; LTE=long-term extension; UC=ulcerative colitis.
†Clinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1.
‡Clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability).
Reference: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.